President & Chair
Steven Bloom is a seasoned executive with 35 years of experience across multiple health care business models. Steve started his career at Eli Lilly and Company where he worked in many senior level roles including PROZAC USA Marketing Leader and Executive Lead in Corporate Affairs which included patient advocacy and allied development. Steve left Lilly to help start up companies Inflexxion (addiction services) and Pharmetrics (health outcomes and patient level analytics) build and scale their business models as the executive responsible for Commercial Planning, Corporate Development and Corporate Strategy. Pharmetrics was subsequently acquired by IMS Health in 2005. Steve joined ZIOPHARM Oncology (ZIOP) as SVP of Corporate Development and Commercial Planning and led the effort to build a business in both the sarcoma and lymphoma disease areas. Most recently Steve served as Chief Strategy Officer at VERASTEM Oncology (VSTM) where his team led the effort to acquire duvelisib which was approved by FDA in September 2018 for CLL and FL. He led the early buildout of the company with a laser like focus on creating a world class medical affairs and patient advocacy team. Steve is currently advising two early stage oncology companies (VAVOTAR Life Sciences and Vigeo Therapeutics) with strategic planning and development. Steve graduated from Northeastern University College of Pharmacy in 1984 and has been an American Cancer Society Road to Recovery driver since 2008.